Phaseline

Companies › Evommune

Evommune: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Neurology, Immunology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EVO756–Phase 2Atopic Dermatitis; MigraineOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07150845EVO756Phase 2Atopic DermatitisImmunologyJul 2026
NCT07616128EVO756Phase 2MigraineNeurologyOct 2027

From the company's SEC filings

Cash and short-term investments of $201m on 2026-06-30; operating cash outflow about $97m a year; runway about 25 months at that burn, to Jul 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Aclaris Therapeutics Coya Therapeutics Cognition Therapeutics DiaMedica Therapeutics Palisade Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.